---
title: "Tuoxin Pharmaceutical: Net profit loss of 11.8805 million yuan in the third quarter, a decrease of 1,258.62%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263074769.md"
description: "Tuoxin Pharmaceutical announced that the revenue for the third quarter was 89.6538 million yuan, a decrease of 16.21%; the net profit loss was 11.8805 million yuan, a decrease of 1,258.62%. The revenue for the first three quarters was 272 million yuan, a decrease of 16.64%; the net profit loss was 30.1611 million yuan, a decrease of 1,036.53%"
datetime: "2025-10-28T11:49:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263074769.md)
  - [en](https://longbridge.com/en/news/263074769.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263074769.md)
generator: "portal-rs"
---

# Tuoxin Pharmaceutical: Net profit loss of 11.8805 million yuan in the third quarter, a decrease of 1,258.62%

Tuoxin Pharmaceutical announced that its revenue for the third quarter was 89.6538 million yuan, a decrease of 16.21%; the net profit loss was 11.8805 million yuan, a decrease of 1,258.62%. Revenue for the first three quarters was 272 million yuan, a decrease of 16.64%; the net profit loss was 30.1611 million yuan, a decrease of 1,036.53%

### Related Stocks

- [301089.CN](https://longbridge.com/en/quote/301089.CN.md)

## Related News & Research

- [Federal Reserve Chairman Warsh: Beware of Inflation Risks in the AI Era; Comprehensive Policy Reform Needed](https://longbridge.com/en/news/297343824.md)
- [Nimiq Opens Second Mini Apps Competition After Strong Debut](https://longbridge.com/en/news/297184111.md)
- [Heidelberg Pharma, Huadong Medicine expand ADC collaboration to develop new drug candidates](https://longbridge.com/en/news/297291658.md)
- [EEOC moves to curb in-house enforcement of anti-bias laws against US agencies](https://longbridge.com/en/news/297088844.md)
- [08:39 ETPredoc Launches Curated Data Layer to Make Fragmented Medical Records Usable](https://longbridge.com/en/news/297187951.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**